← Institutional research
Institutional research
Novel China INDs
Novel products cleared for their first human trials in China. Explore the sponsors, modalities and clearance timeline.
Clearance timeline
Product catalogue
PreviewFirst five product previews
| Product | Sponsor / developer | Country | Modality | Clearance month |
|---|---|---|---|---|
| 24-valent pneumococcal conjugate vaccine | CanSino | China | Vaccine | January 2026 |
| DB1317 | Duality Biologics | China | ADC / conjugate | January 2026 |
| EPI003 | Epigenic Therapeutics | China | RNA / oligonucleotide | January 2026 |
| Human fore/midbrain neural precursor cells | Quansheng (泉生生物) | China | Gene / cell therapy | January 2026 |
| IBI3028 | Innovent | China | ADC / conjugate | January 2026 |
Checking your access…